FRANKLIN, Mass., May 8 /PRNewswire-FirstCall/ -- Sontra Medical Corporation announced today that its common stock is now quoted on the OTC Bulletin Board under the symbol “SONT.OB”. The Company’s common stock was previously quoted on the “Pink Sheets” under the symbol “SONT.PK”.
About Sontra Medical Corporation (http://www.sontra.com)
Sontra Medical Corporation, a technology leader in transdermal science, is developing a non-invasive, continuous transdermal glucose monitor (“CTGM”) for use in the Diabetes and Intensive Care Markets. In addition, the Company owns the FDA approved SonoPrep(R) ultrasound-mediated skin permeation technology, presently used with topical lidocaine to achieve rapid (within five minutes) skin anesthesia. The Company is using its technical competencies in transdermal drug formulation, delivery systems and biosensors to develop a new paradigm in transdermal drug delivery and diagnosis.
SonoPrep is a registered trademark of Sontra Medical Corporation. All other company, product or service names mentioned herein are the trademarks or registered trademarks of their respective owners.
Investor Relations Contact: Harry G. Mitchell, Interim CEO 508-530-0311 hmitchell@sontra.com
Sontra Medical Corporation
CONTACT: Investor Relations: Harry G. Mitchell, Interim CEO of SontraMedical Corporation, +1-508-530-0311, hmitchell@sontra.com
Web site: http://www.sontra.com//
